Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Patients with Malignant pleural effusion can be diagnosis advanced cancer. Currently recognized as the most reliable method to control malignant pleural effusion is pleural fixed or thoracic catheter drainage. The most effective pleural fixed agent is pulvis talci, but there are about 30% relapse rate. Thoracic drainage can lead to some complications, such as chest infections, catheter migration and blockage etc. The investigators need a reliable methods to solve dyspnea and other symptoms caused by malignant pleural effusion, and improve quality of life. The purpose of this study was to determine the efficacy and Safety of intrapleural Bevacizumab versus pulvis talci as treatment for malignant pleural effusions (MPE) in patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tang-Du Hospital
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

1. Diagnose malignant pleural effusions by:

• Diagnose malignant pleural neoplasms by histopathology

• Recurrent pleural effusion, Histologically or cytologically confirmed diagnosis of cancer

2. Written informed consent

Exclusion Criteria:

1. <18years of age

2. Expected survival <3 months

3. Chest infection, chylothorax, pleurodesis or ipsilateral lung surgery once

4. Planned chemotherapy

5. Pregnancy or breast-feeding (women of child-bearing potential)

6. Not signed informed consent or non-compliance with treatment protocols